In addition, we found that the oral administration of AYC-EVs in ovalbumin-sensitized asthmatic mouse models reduced OVA-induced DC maturation, Th2, and Th2/Th17-mediated immune responses, as well as the pathological symptoms (an increase in bronchoconstriction and inflammation) of allergic asthma, and the levels of the major factors (upregulation of Th2 cytokines, IgE, MUC5AC, and eotaxin expressions in serum or BALF) inducing asthma. Here, MUC5AC is linked to asthma.